Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Revvity Inc — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.6, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Revvity Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| KOLD | RVTY | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $49.39 | $117.75 |
52-Week Low | $13.58 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.54, down 0.35% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF tracks natural gas price movements inversely, with recent news highlighting volatility in natural gas markets driven by weather patterns and LNG demand. Support levels cluster around $28 with resistance at $29-$30.
As a leveraged ETF, KOLD carries significant volatility risks and is designed for short-term trading rather than long-term investment. The natural gas market faces headwinds from production levels and storage data, while geopolitical developments and weather patterns create trading opportunities for tactical investors.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
